Drugmaker Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies [...] …
Category: Pharma Industry
Drugmaker Johnson & Johnson will offer refunds to 340B providers related to the purchases of four of its drugs, including [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
In 2023, the battle over the use of contract pharmacy arrangements by 340B providers was marked by increasing drugmaker restrictions, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Months after it was expected, bipartisan legislation to prevent drugmaker restrictions on the use of contract pharmacies by 340B providers [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Missouri state senator has filed to reintroduce a bill that would bar drugmaker 340B contract pharmacy restrictions and pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...] …